Literature DB >> 7668037

Protection of mice from Bordetella pertussis respiratory infection using microencapsulated pertussis fimbriae.

D H Jones1, B W McBride, H Jeffery, D T O'Hagan, A Robinson, G H Farrar.   

Abstract

Conditions have been established which allow the efficient entrapment of Bordetella pertussis fimbriae in poly(lactide-co-glycolide) microspheres. Fimbriae released from the matrix were found to have retained some degree of conformational structure, as determined by assessing the capacity of fimbrial protein to bind to antibodies mapping to either conformational or denatured structures on the fimbriae, either encapsulated in microspheres with a mean diameter of 24 microns and an estimated in vitro protein release rate of approximately 42 days, or conventionally adjuvanted with alhydrogel, elicited vigorous immune responses in mice. The encapsulated fimbriae appear to elicit marginally lower serum antibody levels than those induced by equivalent amounts of alhydrogel-adjuvanted fimbriae. Mice immunised with both preparations were, however, protected against intranasal infection with live B. pertussis as evidenced by the significant reduction in levels of bacterial colonisation observed in the lungs and tracheas of immunised animals when compared to the immunologically naive controls.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7668037     DOI: 10.1016/0264-410x(95)99876-j

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Receptor-mediated targeting of spray-dried lipid particles coformulated with immunoglobulin and loaded with a prototype vaccine.

Authors:  A I Bot; D J Smith; S Bot; L Dellamary; T E Tarara; S Harders; W Phillips; J G Weers; C M Woods
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

2.  On technological and immunological benefits of multivalent single-injection microsphere vaccines.

Authors:  Gérard Boehm; Marisa Peyre; Dorothea Sesardic; Rachel J Huskisson; Fatme Mawas; Alexandra Douglas; Dorothy Xing; Hans P Merkle; Bruno Gander; Pål Johansen
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

3.  Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine.

Authors:  F Zepp; M Knuf; P Habermehl; J H Schmitt; C Rebsch; P Schmidtke; R Clemens; M Slaoui
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

4.  Role of antibodies against Bordetella pertussis virulence factors in adherence of Bordetella pertussis and Bordetella parapertussis to human bronchial epithelial cells.

Authors:  B M van den Berg; H Beekhuizen; F R Mooi; R van Furth
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

5.  Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection.

Authors:  D H Jones; B W McBride; C Thornton; D T O'Hagan; A Robinson; G H Farrar
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

Review 6.  Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1.

Authors:  Yong Gao; Chanuka Wijewardhana; Jamie F S Mann
Journal:  Front Immunol       Date:  2018-02-28       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.